2-Acetamido-N-(tert-butyl)-2-(1-(3,4-dichlorobenzyl)piperidin-4-yl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanamide

Catalog No. :
ACYKVB270
CAS No. :
1508281-70-6
Molecular Formula :
C30H48BCl2N3O4
Molecular Weight :
596.45

IUPAC Name:2-acetamido-N-(tert-butyl)-2-(1-(3,4-dichlorobenzyl)piperidin-4-yl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanamide

2-Acetamido-N-(tert-butyl)-2-(1-(3,4-dichlorobenzyl)piperidin-4-yl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanamide structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name2-Acetamido-N-(tert-butyl)-2-(1-(3,4-dichlorobenzyl)piperidin-4-yl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanamide
IUPAC Name2-acetamido-N-(tert-butyl)-2-(1-(3,4-dichlorobenzyl)piperidin-4-yl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanamide
Molecular FormulaC30H48BCl2N3O4
Molecular Weight596.45
SMILESO=C(NC(C)(C)C)C(C1CCN(CC2=CC=C(Cl)C(Cl)=C2)CC1)(NC(C)=O)CCCCB3OC(C)(C)C(C)(C)O3
InChI KeyLPDLPEYSQVRLDS-UHFFFAOYSA-N
Synonym4-Piperidineacetamide, α-(acetylamino)-1-[(3,4-dichlorophenyl)methyl]-N-(1,1-dimethylethyl)-α-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)butyl]-
CAS No.1508281-70-6

Synthetic Route by SureRoute

1. ACYKVB270 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACYKVB270 route product structure diagram
    ACYKVB2701508281-70-6
Inquiry

2. ACYKVB270 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACYKVB270 route product structure diagram
    ACYKVB2701508281-70-6
Inquiry

Comments (0)